Skip to main content

Publications

63 publications

Active

8 grants
  • PI
    Exploiting tumor metabolism to optimize T cell therapy
    National Cancer Institute · 2021–2029· 2 renewals
    R50CA221810-09
  • Co-I
    Targeting the melanoma metabolic microenvironment to boost T-cell therapy
    Melanoma Research Alliance · 2026–2029
    1584423
  • Co-I
    Effects of tumor energetics on anti-tumor immunity through vasculature remodeling
    The G. Harold and Leila Y. Mathers Foundation · 2025–2028
    GHL 251782-01
  • Co-I
    MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL
    National Cancer Institute · 2025–2027
    R01CA282889-03S1
  • Co-I
    Mechanisms of "fragile" intratumoral regulatory T cells supporting anti-tumor immunity
    Cancer Research Institute, Inc. · 2025–2027
    CRI13928
  • Co-I
    Prostate Cancer Non-Neuroendocrine Lineage Plasticity: Detection Using Multimodal Integration And immunotherapeutic Targeting
    Starr Cancer Consortium · 2024–2026
    I17-0132
  • Co-I
    Image-guided Trp-IDO/TDO-Kyn-AHR pathway inhibition, combined with immunotherapy
    National Cancer Institute · 2022–2026
    R01CA249294-03
  • Co-I
    CD36 in breast cancer
    Pilatus Biosciences Inc · 2025–2026Contract
    SRA 234221-01
Completed grants (2)
  • KP
    Tumor-metabolism-driven therapies to overcome TNBC immune resistance
    Breast Cancer Alliance Inc. · 2023–2025
    BCA 225494-01
  • Co-I
    SRA with BMS
    Bristol-Myers Squibb · 2021–2024Contract
    SRA 215059-02